Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-day Low Dose Aprepitant/Fosaprepitant for Carboplatin CINV
NCT03237611Phase 2Terminated
- Sponsor
- Albert Einstein College of Medicine
- Start
- Oct 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aprepitant and fosaprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Albert Einstein College of Medicine. Primary endpoint: Complete Control Rate of Chemotherapy-induced Nausea and Vomiting (CINV) Following 1st Cycle of Chemotherapy at 24 hours. Started Oct 2018; status: terminated.
02
Drugs
aprepitantfosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT03237611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237611.